{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:35:57Z","timestamp":1792722957177,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sitravatinib is an immunomodulatory tyrosine kinase inhibitor that can augment responses when combined with programmed death-1 inhibitors such as nivolumab. We report a single-arm, interventional, phase 2 study of neoadjuvant sitravatinib in combination with nivolumab in patients with locally advanced clear cell renal cell carcinoma (ccRCC) prior to curative nephrectomy (NCT03680521). The primary endpoint was objective response rate (ORR) prior to surgery with a null hypothesis ORR\u2009=\u20095% and the alternative hypothesis set at ORR\u2009=\u200930%. Secondary endpoints were safety; pharmacokinetics (PK) of sitravatinib; immune effects, including changes in programmed cell death\u2013ligand 1 expression; time-to-surgery; and disease-free survival (DFS). Twenty patients were evaluable for safety and 17 for efficacy. The ORR was 11.8%, and 24-month DFS probability was 88\u00b70% (95% CI 61.0 to 97.0). There were no grade 4\/5 treatment-related adverse events. Sitravatinib PK did not change following the addition of nivolumab. Correlative blood and tissue analyses showed changes in the tumour microenvironment resulting in an immunologically active tumour by the time of surgery (median time-to-surgery: 50 days). The primary endpoint of this study was not met as short-term neoadjuvant sitravatinib and nivolumab did not substantially increase ORR.<\/jats:p>","DOI":"10.1038\/s41467-023-38342-7","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T12:09:13Z","timestamp":1683720553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7697-9591","authenticated-orcid":false,"given":"Jose A.","family":"Karam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8308","authenticated-orcid":false,"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1317-9287","authenticated-orcid":false,"given":"Cara L.","family":"Haymaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1638-1445","authenticated-orcid":false,"given":"Surena F.","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-4491","authenticated-orcid":false,"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3805-7307","authenticated-orcid":false,"given":"Amado J.","family":"Zurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9007-0621","authenticated-orcid":false,"given":"Amishi Y.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio I.","family":"Wistuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Marmonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dzifa Y.","family":"Duose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-1636","authenticated-orcid":false,"given":"Edwin R.","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1253-630X","authenticated-orcid":false,"given":"Luisa Maren Solis","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4513-6123","authenticated-orcid":false,"given":"Caddie","family":"Laberiano-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Hallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis D.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirak","family":"Der-Torossian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar M.","family":"Tannir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"38342_CR1","doi-asserted-by":"publisher","first-page":"e003476","DOI":"10.1136\/jitc-2021-003476","volume":"9","author":"M Oliva","year":"2021","unstructured":"Oliva, M. et al. Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study. J. Immunother. Cancer 9, e003476 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"38342_CR2","doi-asserted-by":"publisher","first-page":"e124184","DOI":"10.1172\/jci.insight.124184","volume":"3","author":"W Du","year":"2018","unstructured":"Du, W., Huang, H., Sorrelle, N. & Brekken, R. A. Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. JCI Insight 3, e124184 (2018).","journal-title":"JCI Insight"},{"key":"38342_CR3","doi-asserted-by":"publisher","first-page":"abstract 4568","DOI":"10.1200\/JCO.2018.36.15_suppl.4568","volume":"36","author":"S Pant","year":"2018","unstructured":"Pant, S. et al. Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT). J. Clin. Oncol. 36, abstract 4568 (2018).","journal-title":"J. Clin. Oncol."},{"key":"38342_CR4","doi-asserted-by":"publisher","first-page":"eabm6420","DOI":"10.1126\/scitranslmed.abm6420","volume":"14","author":"P Msaouel","year":"2022","unstructured":"Msaouel, P. et al. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci. Transl. Med. 14, eabm6420 (2022).","journal-title":"Sci. Transl. Med."},{"key":"38342_CR5","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/iju.13943","volume":"26","author":"SW Berquist","year":"2019","unstructured":"Berquist, S. W. et al. Systemic therapy in the management of localized and locally advanced renal cell carcinoma: current state and future perspectives. Int. J. Urol. 26, 532\u2013542 (2019).","journal-title":"Int. J. Urol."},{"key":"38342_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fonc.2017.00107","volume":"7","author":"BM Shinder","year":"2017","unstructured":"Shinder, B. M. et al. Surgical management of advanced and metastatic renal cell carcinoma: a multidisciplinary approach. Front. Oncol. 7, 107 (2017).","journal-title":"Front. Oncol."},{"key":"38342_CR7","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N. Engl. J. Med. 385, 683\u2013694 (2021).","journal-title":"N. Engl. J. Med."},{"key":"38342_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1177\/1756287215612962","volume":"8","author":"LD Borregales","year":"2016","unstructured":"Borregales, L. D., Adibi, M., Thomas, A. Z., Wood, C. G. & Karam, J. A. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther. Adv. Urol. 8, 130\u2013141 (2016).","journal-title":"Ther. Adv. Urol."},{"key":"38342_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.euo.2021.04.002","volume":"5","author":"MA Gorin","year":"2022","unstructured":"Gorin, M. A. et al. Neoadjuvant nivolumab in patients with high-risk nonmetastatic renal cell carcinoma. Eur. Urol. Oncol. 5, 113\u2013117 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"38342_CR10","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Kidney Cancer v2.2022. https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/kidney-patient.pdf (2021)."},{"key":"38342_CR11","unstructured":"ClinicalTrials.gov. Neoadjuvant AXITINIB and AVELUMAB for patients with localized clear-cell RCC. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03341845."},{"key":"38342_CR12","unstructured":"ClinicalTrials.gov. Lenvatinib and pembrolizumab before surgery for the treatment of locally advanced non-metastatic kidney cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04393350."},{"key":"38342_CR13","doi-asserted-by":"publisher","first-page":"abstract 289","DOI":"10.1200\/JCO.2022.40.6_suppl.289","volume":"40","author":"A Bex","year":"2022","unstructured":"Bex, A. et al. Efficacy, safety, and biomarker analysis of neoadjuvant avelumab\/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx). J. Clin. Oncol. 40, abstract 289 (2022).","journal-title":"J. Clin. Oncol."},{"key":"38342_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien, P. A. et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann. Surg. 250, 187\u2013196 (2009).","journal-title":"Ann. Surg."},{"key":"38342_CR15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2174\/157488411797189415","volume":"6","author":"M Choueiri","year":"2011","unstructured":"Choueiri, M., Tannir, N. & Jonasch, E. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Curr. Clin. Pharmacol. 6, 144\u2013150 (2011).","journal-title":"Curr. Clin. Pharmacol."},{"key":"38342_CR16","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.eururo.2014.01.035","volume":"66","author":"JA Karam","year":"2014","unstructured":"Karam, J. A. et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur. Urol. 66, 874\u2013880 (2014).","journal-title":"Eur. Urol."},{"key":"38342_CR17","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/j.1464-410X.2010.09357.x","volume":"106","author":"JL Silberstein","year":"2010","unstructured":"Silberstein, J. L. et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int. 106, 1270\u20131276 (2010).","journal-title":"BJU Int."},{"key":"38342_CR18","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1001\/jamaoncol.2016.1197","volume":"2","author":"T Powles","year":"2016","unstructured":"Powles, T. et al. Safety and efficacy of pazopanib therapy prior to planned nephrectomy in metastatic clear cell renal cancer. JAMA Oncol. 2, 1303\u20131309 (2016).","journal-title":"JAMA Oncol."},{"key":"38342_CR19","doi-asserted-by":"publisher","first-page":"abstract TPS684","DOI":"10.1200\/JCO.2019.37.7_suppl.TPS684","volume":"37","author":"LC Harshman","year":"2019","unstructured":"Harshman, L. C. et al. PROSPER: a phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). J. Clin. Oncol. 37, abstract TPS684 (2019).","journal-title":"J. Clin. Oncol."},{"key":"38342_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman, W. H., Zitvogel, L., Saut\u00e8s-Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717\u2013734 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"38342_CR21","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ccell.2021.02.013","volume":"39","author":"DA Braun","year":"2021","unstructured":"Braun, D. A. et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 39, 632\u2013648.e8 (2021).","journal-title":"Cancer Cell"},{"key":"38342_CR22","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s43018-022-00391-0","volume":"3","author":"N Kourtis","year":"2022","unstructured":"Kourtis, N. et al. A single\u2013cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma. Nat. Cancer 3, 885\u2013898 (2022).","journal-title":"Nat. Cancer"},{"key":"38342_CR23","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/2326-6066.CIR-15-0043","volume":"3","author":"M Callea","year":"2015","unstructured":"Callea, M. et al. Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol. Res. 3, 1158\u20131164 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"38342_CR24","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney, G. T., Weiner, L. M. & Atkins, M. B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17, e542\u2013e551 (2016).","journal-title":"Lancet Oncol."},{"key":"38342_CR25","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao, J. et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397\u2013404.e9 (2016).","journal-title":"Cell"},{"key":"38342_CR26","doi-asserted-by":"publisher","first-page":"abstract TPS365","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS365","volume":"39","author":"P Msaouel","year":"2021","unstructured":"Msaouel, P. et al. Phase I\/IB trial of sitravatinib (Sitra) + nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies. J. Clin. Oncol. 39, abstract TPS365 (2021).","journal-title":"J. Clin. Oncol."},{"key":"38342_CR27","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1158\/2326-6066.CIR-19-0146","volume":"7","author":"H Zelba","year":"2019","unstructured":"Zelba, H. et al. PD-1 and LAG-3 dominate checkpoint receptor\u2013mediated T-cell inhibition in renal cell carcinoma. Cancer Immunol. Res. 7, 1891\u20131899 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"38342_CR28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1177\/1740774510382799","volume":"7","author":"Y Ji","year":"2010","unstructured":"Ji, Y., Liu, P., Li, Y. & Bekele, B. N. A modified toxicity probability interval method for dose-finding trials. Clin. Trials 7, 653\u2013663 (2010).","journal-title":"Clin. Trials"},{"key":"38342_CR29","unstructured":"Bristol-Myers Squibb Company. OPDIVO\u00ae (nivolumab) injection, for intravenous use [package insert]. https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf (2018)."},{"key":"38342_CR30","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"38342_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"38342_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/cancers12020255","volume":"12","author":"ER Parra","year":"2020","unstructured":"Parra, E. R. et al. Procedural requirements and recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification assays to support translational oncology studies. Cancers 12, 255 (2020).","journal-title":"Cancers"},{"key":"38342_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-83858-x","volume":"11","author":"ER Parra","year":"2021","unstructured":"Parra, E. R. et al. Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues. Sci. Rep. 11, 4530 (2021).","journal-title":"Sci. Rep."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38342-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38342-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38342-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T12:09:48Z","timestamp":1683720588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38342-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["38342"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-38342-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"27 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.A.K. reports honoraria for scientific advisory board memberships\/consulting for Merck, Pfizer, Johnson and Johnson; stock ownership in MedTek, ROMTech; research funding to institution from Mirati, Roche\/Genentech, Merck, Elypta. P.M. reports honoraria for scientific advisory boards membership for Mirati Therapeutics, Bristol-Myers Squibb, and Exelixis; consulting fees from Axiom Healthcare; non-branded educational programmes supported by Exelixis and Pfizer; leadership or fiduciary roles as a Medical Steering Committee Member for the Kidney Cancer Association and a Kidney Cancer Scientific Advisory Board Member for KCCure; and research funding from Takeda, Bristol-Myers Squibb, Mirati Therapeutics, and Gateway for Cancer Research. C.L.H. reports consulting fees from Nanobiotix, stock options for scientific advisory board membership from Briacell, research funding to institution from Iovance, Dragonfly, Sanofi, Avenge and Mirati, honoraria from SITC and SWOG. S.F.M. reports consulting relationships with Merck and Johnson & Johnson; and clinical trial support for QED. M.T.C. reports consulting\/advisory relationships with ApricityHealth, AstraZeneca, AXDev, EMD Serono, Exelixis, Seagen, and Pfizer; research funding from ApricityHealth, AstraZeneca, Aveo, EMD Serono, Exelixis, Janssen, and Pfizer; honoraria from AstraZeneca, AXDev, BMS, DAVA, EMD Serono, Exelixis, Merck, Roche, Pfizer, Seagen, and SITC; has received support for attending meetings and\/or travel from the Kidney Cancer Association; and holds a leadership or fiduciary role as part of the Kidney Cancer Association Steering Committee. A.J.Z. reports consulting\/advisory relationships with Amedco, AstraZeneca, Bayer, Biocept, CancerNet, LLC., Incyte, and Pfizer; research funding from Infinity Pharma and Pfizer; and honoraria from Amedco, AstraZeneca, CancerNet, LLC., Janssen-Cilag, McKesson Specialty Health, and Pfizer. A.Y.S. reports research funding from Bristol-Myers Squibb, Eisai, and EMD Serono; and receipt of equipment, materials, drugs, medical writing, gifts or other services from Bristol-Myers Squibb, Eisai, EMD Sereona, and 4D Pharma. I.I.W. reports grants\/contracts to their institution from Genentech, HTG Molecular, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adaptimmune Therapeutics, EMD Sereno, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, Iovance, 4D Pharma, Novartis, and Akoya; consulting fees from Roche, Bayer, Bristol-Myers Squibb, AstraZeneca, Pfizer, HTG Molecular, Merch, GlaxoSmithKline, GuardantHealth, Novartis, Flame, Sanofi, Janssen, Daiichi Sankyo, Oncocyte, Amgen, and MSD; and payment\/honoraria from Medscape, Roche, Pfizer, AstraZeneca, Platform Health, and Merck. D.D. reports honoraria from Chrysalis Biomedical Advisors. E.M., E.R.P., L.M.S.S., C.L.-F., M.L., A.A. have no relevant conflicts to disclose. M.H., C.D.C., P.O., X.Y., and H.D.-T. are employees and stockholders of Mirati Therapeutics, Inc. N.M.T. reports grants\/contracts from Bristol-Myers Squibb, Nektar Therapeutics, Calithera Bioscience, Arrowhead Pharmaceuticals, Eisai, and Novartis; and consulting fees from Oncorena; honoraria for advisory meetings, presentations, and educational events from Bristol-Myers Squibb, Nektar Therapeutics, Exelixis, Eisai, Eli Lilly, Oncorena, Calithera, Surface Oncology, Novartis, Ipsen, and Merck Sharp & Dohme; participation on a data safety monitoring board or advisory board as a member of the US RCC Advisory Board Committee for Merck; and is a stockholder of Amgen, Arcturus Therapeutics, Arcus Biosciences, Bellus Health, BioCryst, Corvus Pharmaceuticals, First Trust Amex Biotech, Johnson & Johnson, Merck, Nuvation Bio, Revolution Medicines, Spdr S&P Pharmaceuticals, Surface Oncology, Vanguard Healthcare Solutions, and Xencor.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2684"}}